Sesen Bio, af­ter years on the edge of ir­rel­e­van­cy, scores speedy re­view for long ges­tat­ing blad­der can­cer pro­gram

Af­ter years spent in the pen­ny stock range, Sesen Bio has nabbed a long-await­ed FDA re­view for its an­ti­body-drug con­ju­gate blad­der can­cer pro­gram.

The FDA will give an ac­cel­er­at­ed au­dit to Sesen and its blad­der can­cer can­di­date Vicineum, an an­ti­body-drug con­ju­gate ac­quired in the com­pa­ny’s buy­out of Toron­to-based Viven­tia back in 2016. Sesen is pen­ciled in for an Aug 18 PDU­FA, and there is no ad­comm on the dock­et right now, the com­pa­ny said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER